Suppression of Experimental Allergic Encephalomyelitis by NSC 82196, a New Imidazole Carboxamide Derivative

Charles L. Vogel, Vincent T. De Vita, Robert P. Lisak, Marian W. Kies

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Experimental allergic encephalomyelitis (EAE) was used as a model delayed hypersensitivity reaction to test the immunosuppressive potential of the new carcinostatic agent, imidazole-4(or 5)-carboxamide,5(or 4)-[3,3-bis-(2-chloroethyl)-l-triazeno] (NSC 82196). EAE was induced in the highly susceptible Lewis strain of rats by intradermal injection of an encephalitogenic protein extracted from guinea pig brain emulsified in Freund's complete adjuvant. NSC 82196 delayed the onset and significantly decreased the severity of EAE when given prior to antigenic challenge. This drug was more effective in suppressing EAE than equitoxic doses of a related compound, NSC 45388, and the other immunosuppressive agents tested, cyclophosphamide, nitrogen mustard, azathioprine, and amethopterin, when all drugs were given in a similar presensitization schedule. EAE can be used as an effective screening model for immunosuppressive effects of drugs that may have pertinence in cancer chemotherapy.

Original languageEnglish (US)
Pages (from-to)2249-2253
Number of pages5
JournalCancer Research
Volume29
Issue number12
StatePublished - Dec 1969
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Suppression of Experimental Allergic Encephalomyelitis by NSC 82196, a New Imidazole Carboxamide Derivative'. Together they form a unique fingerprint.

  • Cite this